BeyondSpring Set to Join FTSE Russell 3000® Index
June 20, 2019 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join...
New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
February 26, 2019 07:30 ET
|
BeyondSpring, Inc.
BeyondSpring to Present Results at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical...
BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
January 26, 2018 08:00 ET
|
BeyondSpring, Inc.
Plinabulin and Neulasta have Very Similar Grade 4 Neutropenia Incidence and Duration of Severe Neutropenia (DSN) in the Phase 2 Portion of Phase 2/3 Trial Study 105 with Docetaxel-Induced Neutropenia ...
BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)
December 14, 2017 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China
December 04, 2017 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority
November 30, 2017 09:58 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
October 26, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
October 23, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
October 18, 2017 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 18, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention
July 06, 2017 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...